Avadel Pharmaceuticals (AVDL) Accumulated Expenses: 2009-2022
Historic Accumulated Expenses for Avadel Pharmaceuticals (AVDL) over the last 14 years, with Sep 2022 value amounting to $8.0 million.
- Avadel Pharmaceuticals' Accumulated Expenses fell 8.85% to $8.0 million in Q3 2022 from the same period last year, while for Sep 2022 it was $8.0 million, marking a year-over-year decrease of 8.85%. This contributed to the annual value of $7.2 million for FY2021, which is 10.00% up from last year.
- As of Q3 2022, Avadel Pharmaceuticals' Accumulated Expenses stood at $8.0 million, which was down 17.67% from $9.7 million recorded in Q2 2022.
- Avadel Pharmaceuticals' 5-year Accumulated Expenses high stood at $45.9 million for Q1 2018, and its period low was $4.3 million during Q1 2021.
- In the last 3 years, Avadel Pharmaceuticals' Accumulated Expenses had a median value of $8.7 million in 2021 and averaged $9.9 million.
- In the last 5 years, Avadel Pharmaceuticals' Accumulated Expenses skyrocketed by 130.48% in 2018 and then tumbled by 71.08% in 2021.
- Over the past 5 years, Avadel Pharmaceuticals' Accumulated Expenses (Quarterly) stood at $21.7 million in 2018, then declined by 8.69% to $19.8 million in 2019, then slumped by 67.18% to $6.5 million in 2020, then rose by 10.00% to $7.2 million in 2021, then declined by 8.85% to $8.0 million in 2022.
- Its Accumulated Expenses was $8.0 million in Q3 2022, compared to $9.7 million in Q2 2022 and $9.4 million in Q1 2022.